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Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella 
pneumoniae. Recently, this has driven clinical deployment of the β-lactam/β-lactamase 
inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam. We show that four 
steps: ompK36 and ramR mutation plus carriage of OXA-232 and KPC-3-D178Y variant 
β-lactamases confer ceftazidime/avibactam and meropenem/vaborbactam resistance 
when both pairs are used together. These findings have implications for decision 
making about sequential and combinatorial use of these β-lactam/β-lactamase inhibitor 





K. pneumoniae can become third-generation cephalosporin (3GC) and/or carbapenem 
resistant through acquisition of a wide range of serine β-lactamases (1). Most clinically 
significant are the CTX-M (2), KPC (3) and the OXA-48-like (4) types. In response to the rise 
of KPC, which can confer 3GC and carbapenem resistance, serine β-lactamase inhibitors 
have recently been developed, including avibactam and vaborbactam. Avibactam (5) is used 
in combination with the 3GC ceftazidime. It inhibits CTX-M, KPC and OXA-48-like β-
lactamases (6,7). Ceftazidime/avibactam (CAZ/AVI) non-susceptibility can be caused by KPC 
changes, e.g. D179Y or V239G (8,9) or by a P170S change in CTX-M (10). Vaborbactam is 
used in combination with the carbapenem meropenem (11). It has potent activity against KPC, 
and, to a lesser extent, CTX-M (12). Meropenem/vaborbactam (MER/VAB) resistance in K. 
pneumoniae is caused by loss of OmpK36 and OmpK35 porins in backgrounds carrying KPC 
or OXA-48 like enzymes (12,13). 
Given the appearance of K. pneumoniae clinical isolates resistant to MER/VAB or CAZ/AVI, it 
has been suggested that a combination of both given together would overcome isolates 
resistant to one or both when used separately (14,15). The aim of the work reported here was 
to identify steps that can generate resistance to MER/VAB or CAZ/AVI when used together. 
Firstly, a plasmid (pOXA-232) encoding the OXA-48-like carbapenemase OXA-232 was 
purified from K. pneumoniae clinical isolate KP11 (16) and used to transform the ramR 
frameshift (Arg44FS) mutant clinical K. pneumoniae isolate KP21 (16) using 8 µg.mL-1 
piperacillin and 4 µg.mL-1 tazobactam as selection. This isolate was chosen because ramR 
mutation causes over-production of the AcrAB-TolC efflux pump and reduced production of 
the OmpK35 porin, and this enhances the spectrum of resistance conferred by OXA-48 and 
other β-lactamases in K. pneumoniae (17). However, despite its ramR mutation, the MIC of 
meropenem (CLSI microtitre assay [18]) in the presence of 8 µg.mL-1 vaborbactam 
(MedChemExpress) against KP21(pOXA-232) was 1 µg.mL-1 (Table 1), making it MER/VAB 




MER/VAB resistant derivative. To do this 100 µL aliquots of overnight cultures of KP21(pOXA-
232) grown in Nutrient Broth were spread onto Mueller Hinton agar containing 16 µg.mL-1 
meropenem and 8 µg.mL-1 vaborbactam, which was then incubated for 24 h at 37°C.  
LC-MS/MS envelope proteomics, performed as described previously (17) confirmed that this 
putative MER/VAB resistant mutant, KP21 M(pOXA-232), had undetectable OmpK36 porin 
levels. Whole genome sequencing, performed as described previously (20), identified a single 
mutation resulting in a stop at codon 125 in ompK36 in KP21 M(pOXA-232). To confirm the 
effect of this ompK36 point mutation we insertionally inactivated ompK36 in the parent strain 
KP21(pOXA-232) using the pKNOCK suicide plasmid (21). The ompK36 DNA fragment was 
amplified from K. pneumoniae Ecl8 (22) genomic DNA using primers ompK36 KO FW (5′-
CGTTCAGGCGAACAACACTG-3′) and ompK36 KO RV (5′-AAGTTCAGGCCGTCAACCAG-
3′). The PCR product was ligated into the pKNOCK-GM at the SmaI site. The recombinant 
plasmid was then transferred into KP21(pOXA-232) by conjugation. Mutants were selected 
using gentamicin (5 µg.mL-1) and confirmed by PCR using primers ompK36 full length FW (5′-
GAGGCATCCGGTTGAAATAG-3′) and ompK36 full length RV (5′-
ATTAATCGAGGCTCCTCTTAC-3′). The MER/VAB MIC against the ompK36 point mutant 
KP21 M(pOXA-232) and against the insertionally inactivated mutant KP21 ompK36(pOXA-
232) was 256/8 µg.mL-1 (Table 1) confirming resistance. This finding reveals that OmpK35 
downregulation seen in ramR mutants mimics the effect of OmpK35 loss previously shown to 
be essential alongside OmpK36 loss for MER/VAB resistance in K. pneumoniae producing an 
OXA-48-like enzyme (12,13).  
Both KP21(pOXA-232) ompK36 mutants remained susceptible to ceftazidime (Table 1) as 
expected since OXA-232 only weakly hydrolyses ceftazidime (23). Aiming to increase 
ceftazidime MICs, we introduced the low-copy-number recombinant plasmid pCTX-M-14. To 
make pCTX-M-14, blaCTX-M-14 was amplified alongside its native promoter from a human urinary 
E. coli isolated from primary care (24) using primers CTX-M-14 FW (5′-




CCGGAATTCCGTAGCGGAACGTTCATCAG-3′) and ligated into pUBYT (25) at the EcoRI 
site. Carriage of pUBYT recombinants was selected using kanamycin (30 µg.mL-1). 
Even though CTX-M-14 only weakly hydrolyses ceftazidime (26), in the ramR mutant, KP21, 
carriage of pCTX-M-14 conferred ceftazidime resistance, as seen in KP21(pOXA-232)(pCTX-
M-14), KP21 M(pOXA-232)(pCTX-M-14) and KP21 ompK36(pOXA-232)(pCTX-M-14) (Table 
1). These derivatives remained ceftazidime susceptible in the presence of 4 µg.mL-1 
avibactam (MedChemExpress), however (Table 1), which is a potent inhibitor of CTX-M (5). 
Replacement of blaCTX-M-14 with blaCTX-M-14-P170S, encoding a variant associated with reduced 
CAZ/AVI susceptibility (10), representing the naturally occurring variant CTX-M-19 (27), drove 
the CAZ/AVI MIC against KP21 ompK36(pOXA-232) and KP21 M(pOXA-232) up to 8/4 µg.mL-
1, which is one doubling dilution below the breakpoint for resistance. To enable this, CTX-M-
14 site-directed mutagenesis was performed directly on the recombinant plasmid pCTX-M-14 
using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent, USA) with the primer 
CTX-M-14-P170S-FW (5′-TCTGGATCGCACTGAATCTACGCTGAATACCGC-3′).  
We next insertionally inactivated ompK35 in KP21 M[ompK36](pOXA-232)(pCTX-M-14-
P170S) using the method described above but with the primers ompK35 KO FW (5′-
TCCCAGACCACAAAAACCCG-3′) and ompK35 KO RV (5′-CCAGACCGAAGAAGTCGGAG-
3′) and checked with primers ompK35 full length FW (5′-CACTTCGATGTATTTAACCAG-3′) 
and ompK35 full length RV (5′-ATGATGAAGCGCAATATTCTG-3′). However, this did not 
further increase the CAZ/AVI MIC, confirming that ramR mutation phenotypically mimics 
OmpK35 loss (Table 1). Accordingly, it was not possible for us to generate derivatives 
resistant to both MER/VAB and CAZ/AVI using CTX-M-14-P170S, even in a ramR, ompK36, 
ompK35 triple mutant background co-producing OXA-232. 
KPC-3 is a carbapenemase that can also confer ceftazidime resistance (28). To create the 
recombinant plasmid pKPC-3, blaKPC-3 was amplified from pKpQIL isolated from K. 
pneumoniae KP30 (16) by PCR using primers KPC-3 FW (5′- 




GGCTCTGAAAATCATCTATTGGAATTCCGG-3′) and ligated into pUBYT at the EcoRI site. 
We also generated KPC-3 variants associated with CAZ/AVI resistance (8). KPC-3 site-
directed mutagenesis was performed using a two-step PCR-based strategy: blaKPC-3-D178Y was 
constructed using primers KPC-3-D178Y-FW (5′-AGGCGATGCGCGCTATACCTCATCGCC-
3′) and KPC-3-D178Y-RV (5′- GGCGATGAGGTATAGCGCGCATCGCCT-3′); blaKPC-3-V239G 
was constructed using primers KPC-3-V239G-FW (5′-
GGAACCTGCGGAGGGTATGGCACGGCA-3′) and KPC-3-V239G-RV (5′-
TGCCGTGCCATACCCTCCGCAGGTTCC-3′). The common flanking primers were KPC-3 
FW and KPC-3 RV, as above.  
When introduced into KP21(pOXA-232) (i.e. with wild-type ompK36), both pKPC-3-D178Y or 
pKPC-3-V239G conferred CAZ/AVI resistance, but pKPC-3 did not. The D178Y variant did 
this at the expense of reducing meropenem MIC into the intermediate-resistant zone (Table 
1) as reported previously (8). The V239G variant did not suffer from such a large drop in 
meropenem MIC, but MER/VAB MICs were the same (and in the susceptible range) against 
KP21(pOXA-232) derivatives producing KPC-3 or its D178Y or V239G variants (Table 1). 
Accordingly, it was not possible to generate derivatives resistant to both MER/VAB and 
CAZ/AVI using KPC-3 variants in a background having wild-type ompK36. 
Next, we introduced plasmids encoding the KPC-3 variants associated with CAZ/AVI 
resistance into the ompK36 mutant MER/VAB resistant derivatives KP21 M(pOXA-232) and 
KP21 ompK36(pOXA-232). As expected, the result was resistance to CAZ/AVI and MER/VAB, 
when used separately (Table 1). OXA-232 production is not essential for this phenotype since 
KP21 ompK36(pKPC-3-D178Y) and KP21 ompK36(pKPC-3-V239G) – i.e. lacking OXA-232 
– were also resistant to CAZ/AVI and MER/VAB when used separately (Table 1). Furthermore, 
we found that CAZ/AVI plus MER/VAB resistance can be conferred by production of wild-type 
KPC-3 in a ramR ompK36 double mutant carrying OXA-232 (Table 1). Clinical K. pneumoniae 




been identified that are CAZ/AVI resistant (29) which supports our finding here that KPC-3 
mutation is not essential.  
Finally, checkerboard assays (Figure 1) were performed using an adapted microtiter MIC 
assay to test whether CAZ/AVI and MER/VAB would work synergistically against derivatives 
resistant to both pairs when used separately. Briefly, a PBS bacterial suspension was 
prepared to obtain a stock of OD600=0.01. The final volume in each well of a 96-well cell culture 
plate (Corning Costar) was 200 µL and included 20 µL of the bacterial suspension. All wells 
contained Cation Adjusted Muller Hinton broth (CA-MHB) with avibactam (4 µg.mL-1) and 
vaborbactam (8 µg.mL-1) with serial dilutions of meropenem and ceftazidime. Bacterial growth 
(OD600) was determined after 20 h using a POLARstar Omega spectrophotometer (BMG 
Labtech). These assays (Figure 1) confirmed that KP21 M(pOXA-232) and KP21 
ompK36(pOXA-232) carrying pCTX-M14-P170S, pKPC-3 or pKPC-3-V239G were all 
susceptible to meropenem in the presence of vaborbactam plus CAZ/AVI suggesting that 
combined therapy would still work. Further disruption of ompK35 did not alter this result. 
However, KP21 M(pOXA-232)(pKPC-3-D178Y) or KP21 ompK36(pOXA-232)(pKPC-3-
D178Y) were resistant to meropenem (MIC = 16 µg.mL-1) and ceftazidime (MIC ≥ 64 µg.mL-1) 
in the presence of vaborbactam plus avibactam.  
We have, therefore, generated K. pneumoniae derivatives resistant to CAZ/AVI and 
MER/VAB, when used separately when both pairs are used together. This was achieved in 
four steps relative to wild-type: ramR frameshift mutation, acquisition of OXA-232, ompK36 
frameshift mutation (or insertional inactivation), acquisition of KPC-3-D178Y. When we 
constructed a derivative of clinical isolate KP47 (wild type for ramR [16]) carrying pOXA-232 
and pKPC-3-D178Y and with ompK36 insertionally inactivated as described above, the 
derivative was resistant to CAZ/AVI and MER/VAB when used separately (Table 1) but not 
when used together (Figure 1). When we constructed a derivative of KP21 ompK36 carrying 
pKPC-3-D178Y but not pOXA-232 it was also resistant to CAZ/AVI and MER/VAB when used 




and production of OXA-232 are both necessary for the dual-resistant phenotype. Since OXA-
232 has a relatively low level of carbapenemase activity compared with the more commonly 
encountered OXA-48 (23) we are confident that this finding is representative of the wider 
family of OXA-48-like enzymes. 
In conclusion, this work confirms the remarkable capacity of K. pneumoniae to acquire 
resistance to the latest combination therapies available in the clinic by layering mechanisms. 
Of course, the order that the four identified steps occur does not affect the result. So, it would 
seem prudent to make every effort to identify, via molecular diagnostics, intermediate stages 
in this acquisition process. It would also seem prudent not to rely on sequential use of CAZ/AVI 
and MER/VAB, which might select for the dual-resistant phenotype observed here. 
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Figure 1. Checkerboard assays for ceftazidime and meropenem in the presence of 
avibactam and vaborbactam.  
Each image represents duplicate assays for an 8×8 array of wells in a 96-well plate. All wells 
contained CA-MHB including avibactam (4 µg.mL-1) and vaborbactam (8 µg.mL-1). A serial 
dilution of meropenem (MEM, x-axis) and ceftazidime (CAZ, y-axis) was created from 32 
µg.mL-1 in each plate as recorded. All wells were inoculated with a suspension of bacteria, 
made as per CLSI microtiter MIC guidelines (18), and the plate was incubated at 37°C for 20 
h. Growth was recorded by measuring OD600 and growth above background (broth) is 
recorded as a yellow block. Growth at 8 µg.mL-1 ceftazidime and 8 µg.mL-1 meropenem (this 
position indicated in red) in the presence of vaborbactam and avibactam defines resistance 
based on CLSI breakpoints (19). Bacterial suspensions used were: for images in the top 
row, KP21[ramR] ompK36; second row, KP21[ramR] ompK36(pOXA-232); third row, 
KP21[ramR] M[ompK36](pOXA-232); fourth row, KP21[ramR] M[ompK36] ompK35(pOXA-
232); fifth row, KP47 ompK36(pOXA-232). In each case, bacteria also carry the following 
plasmids (where tested): images in first column, pCTX-M-14 P170S; second column, pKPC-





Table 1. MICs (µg.mL-1) of meropenem with or without vaborbactam and of ceftazidime 









232)(pUBYT) 1 1/8 2 0.5/4 
KP21[ramR] pOXA-
232)(pCTX-M-14) 1 1/8 32 1/4 
KP21[ramR] pOXA-
232)(pCTX-M-14 P170S) 1 1/8 256 4/4 
KP21[ramR](pOXA-
232)(pKPC-3) 128 2/8 >256 8/4 
KP21[ramR](pOXA-
232)(pKPC-3-D178Y) 2 2/8 >256 256/4 
KP21[ramR](pOXA-
232)(pKPC-3-V239G) 64 4/8 >256 128/4 
KP21[ramR] 
ompK35(pOXA-
232)(pUBYT) 4 4/8 2 0.5/4 
KP21[ramR] 
ompK35(pOXA-232)(pCTX-
M-14) 4 4/8 32 1/4 
KP21[ramR] 
ompK35(pOXA-232)(pCTX-
M-14 P170S) 2 2/8 >256 4/4 
KP21[ramR] 
ompK35(pOXA-232)(pKPC-
3) 128 1/8 >256 0.125/4 
KP21[ramR] 
ompK35(pOXA-232)(pKPC-






3-V239G) 64 4/8 >256 32/4 
KP21[ramR] 
ompK36(pOXA-
232)(pUBYT) 256 256/8 2 0.5/4 
KP21[ramR] 
ompK36(pOXA-232)(pCTX-
M-14) 256 256/8 32 1/4 
KP21[ramR] 
ompK36(pOXA-232)(pCTX-
M-14 P170S) 256 256/8 >256 8/4 
KP21[ramR] 
ompK36(pOXA-232)(pKPC-
3) >256 256/8 >256 16/4 
KP21[ramR] 
ompK36(pOXA-232)(pKPC-
3-D178Y) 256 256/8 >256 >256/4 
KP21[ramR] 
ompK36(pOXA-232)(pKPC-
3-V239G) >256 256/8 >256 128/4 
KP21[ramR] 
ompK36(pKPC-3) >256 16/8 >256 8/4 
KP21[ramR] 
ompK36(pKPC-3-D178Y) 64 16/8 >256 256/4 
KP21[ramR] 
ompK36(pKPC-3-V239G) >256 32/8 >256 256/4 
KP21 M[ramR ompK36] 
(pOXA-232)(pUBYT) 256 256/8 2 1/4 
KP21 M[ramR ompK36] 
(pOXA-232)(pCTX-M-14) 128 128/8 32 1/4 
KP21 M[ramR ompK36] 
(pOXA-232)(pCTX-M-14 
P170S) 256 128/8 >256 8/4 
KP21 M[ramR ompK36] 




KP21 M[ramR ompK36] 
(pOXA-232)(pKPC-3-D178Y) 128 128/8 >256 256/4 
KP21 M[ramR ompK36] 
(pOXA-232)(pKPC-3-V239G) >256 256/8 >256 64/4 
KP21 M[ramR ompK36]  
ompK35(pOXA-
232)(pUBYT) 256 256/8 2 1/4 
KP21 M[ramR ompK36]  
ompK35(pOXA-232)(pCTX-
M-14) 256 256/8 32 1/4 
KP21 M[ramR ompK36]  
ompK35(pOXA-232)(pCTX-
M-14 P170S) 256 256/8 256 8/4 
KP21 M[ramR ompK36]  
ompK35(pOXA-232)(pKPC-
3) >256 256/8 >256 16/4 
KP21 M[ramR ompK36]  
ompK35(pOXA-232)(pKPC-
3-D178Y) 256 256/8 >256 >256/4 
KP21 M[ramR ompK36]  
ompK35(pOXA-232)(pKPC-
3-V239G) >256 256/8 >256 128/4 
KP47 ompK36(pKPC-3) >256 2/8 >256 8/4 
KP47 ompK36(pKPC-3-
D178Y) 8 2/8 >256 256/4 
KP47 ompK36(pOXA-
232)(pKPC-3) >256 16/8 >256 16/4 
KP47 ompK36(pOXA-
232)(pKPC-3-D178Y) 16 16/8 >256 >256/4 
Shading indicates non-susceptibility (resistance or intermediate resistance) according to CLSI 
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